MedTrace Logo

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma

NCT06068400 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2026-03-17

No results posted yet for this study

Summary

This is a single arm, single center clinical study evaluating the safety and efficacy of CAR-T treatment for relapsed or refractory multiple myeloma.

Conditions

Interventions

BIOLOGICAL

BCMA/GPRC5D dual CAR-T

BCMA/GPRC5D dual CAR-T is a new type CAR-T cells therapy for patients with Relapsed or Refractory Multiple Myeloma.

Sponsors & Collaborators

  • Shenzhen Qianhai Shekou Free Trade Zone Hospital

    collaborator UNKNOWN

  • Guangzhou Bio-gene Technology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Yang Xiao, MD · Shenzhen Qianhai Shekou Free Trade Zone Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-21
Primary Completion
2024-02-02
Completion
2024-02-02

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06068400 on ClinicalTrials.gov